Jane Street
CERE

Jane Street’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Jane Street’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,800
Closed -$499K – 10411
2024
Q1 		$499K Sell
11,800
-27,500
-70% -$1.16M ﹤0.01% 6666
2023
Q4 		$1.67M Sell
39,300
-4,700
-11% -$135K ﹤0.01% 4656
2023
Q3 		$961K Buy
44,000
+12,500
+40% +$313K ﹤0.01% 5235
2023
Q2 		$1M Sell
31,500
-22,600
-42% -$694K ﹤0.01% 5180
2023
Q1 		$1.32M Sell
54,100
-14,300
-21% -$420K ﹤0.01% 4513
2022
Q4 		$2.16M Buy
68,400
+18,700
+38% +$528K ﹤0.01% 3753
2022
Q3 		$1.41M Buy
49,700
+32,200
+184% +$959K ﹤0.01% 4813
2022
Q2 		$463K Sell
17,500
-10,100
-37% -$287K ﹤0.01% 6879
2022
Q1 		$966K Sell
27,600
-5,900
-18% -$172K ﹤0.01% 6211
2021
Q4 		$1.09M Sell
33,500
-2,500
-7% -$88.2K ﹤0.01% 5725
2021
Q3 		$1.06M Buy
+36,000
New +$1.01M ﹤0.01% 5791

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Jane Street's CERE Position: Q3 2024 in Review

Jane Street sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 269,948 shares — an estimated $11M sold.

Jane Street first reported a position in CERE in Q2 2021 and held it in 10 quarters. The position peaked at $11M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Jane Street reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Jane Street sold 269,948 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $11M.
  • Jane Street first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2021 and held it in 10 quarters.
  • Jane Street's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $11M in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Jane Street's 13F filing for Q3 2024, filed 15 Nov 2024.